English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This document sets out the results of a study aimed at estimating the therapeutic efficacy of ivermectin as an adjuvant in the treatment of COVID-19 patients treated at the Specialty Hospital Vida Mejor of the Institute of Social Security for Workers of the State of Chiapas, ISSTECH, Mexico. Ivermectin as an adjuvant in the treatment of COVID-19 patients is more effective (92%) outpatient patients. In critical hospitalized and severe hospitalized patients, ivermectin had a significant impact, both in improving patients' health and decreasing lethality.

international journal of innovative science and research technology

Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19 Study conducted at the Social Security Institute for Workers of the State of Chiapas, ISSTECH, Mexico